Piramal Pharma anticipates a significant turnaround in financial year 2026-27 (FY27), projecting early-to-mid teens revenue expansion and a sharp improvement in profitability, driven by improved business momentum, new product acquisitions, and structural tailwinds.
Uploaded by:
Rediff Video Desk
on Fri, 08 May 2026 09:00:00 +0530
Views: 28
Tags: Piramal Pharma looks to return on growth path